Granisetron Actavis (Granisetron)

Granisetron Actavis is indicated for the prevention of nausea and vomiting in specific clinical settings.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV).
• Prevention of postoperative nausea and vomiting (PONV).
• Use as part of a prophylactic regimen before highly emetogenic chemotherapy.
• Use in patients receiving moderate‑risk chemotherapy agents.
• May be prescribed for nausea associated with radiotherapy.

The safety profile of Granisetron Actavis includes both common and less frequent adverse reactions.

Common

• Headache.
• Constipation.
• Dizziness or light‑headedness.
• Fatigue.
• Mild diarrhea.
• Abdominal discomfort.

Serious

• Severe allergic reaction (anaphylaxis).
• QT interval prolongation.
• Cardiac arrhythmia.
• Severe constipation leading to bowel obstruction.
• Rare cases of serotonin syndrome.

Before initiating Granisetron Actavis, clinicians should consider several precautionary measures.

• Assess cardiac history, especially any prior QT interval prolongation.
• Review concomitant medications that may affect cardiac conduction.
• Use caution in patients with electrolyte disturbances such as hypokalemia or hypomagnesemia.
• Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Consider renal or hepatic impairment when determining dosage.
• Avoid use in patients with a documented prolonged QT syndrome.

Granisetron Actavis can interact with other drugs, influencing its efficacy or safety.

Avoid

• Co‑administration with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics).
• Concurrent use with potent CYP3A4 inhibitors (e.g., ketoconazole) that may increase granisetron plasma levels.

Use with caution

• Use with other antiemetics that also block 5‑HT3 receptors, as additive side effects may occur.
• Use with drugs that affect electrolyte balance (e.g., diuretics).
• Use with medications that may cause dizziness or CNS depression (e.g., benzodiazepines).